89bio Breakthrough Therapy Designation for Pegozafermin in NASH

 Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin–

–Discussions with regulatory agencies regarding the NASH Phase 3 program planned for the fourth quarter of 2023–

https://finance.yahoo.com/news/89bio-announces-u-fda-granted-120000255.html